Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Innovo Therapeutics Inc. is currently managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. This distribution indicates that each of the pending office actions is being handled by a different examiner in a different administrative section. Examiner LEE, CHIHYI NMN is identified as the busiest examiner, though they are only responsible for 1 pending office action.
This 1 action is part of the total workload. The involvement of 2 distinct art units suggests that the company's filings cover different technical sub-sectors within the broader Biotechnology & Pharmaceuticals field. Managing multiple examiners across different units requires a coordination effort to ensure consistency. The company must adapt its prosecution strategy to the specific requirements and examiner tendencies found in each separate administrative environment. Practitioners should monitor the specific habits of LEE, CHIHYI NMN while also tracking the other active files. This structure means that the outcome of one case may not necessarily predict the results of the other.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, CHIHYI NMN | 1 | 33.3% | +61.1% |
| WILSON, JERICA KATLYNN | 1 | 60.5% | +39.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18721811 | NOVEL ISOINDOLINONE DERIVATIVE COMPOUNDS AS CASPASE INHIBITORS | LEE, CHIHYI NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18721811 | NOVEL ISOINDOLINONE DERIVATIVE COMPOUNDS AS CASPASE INHIBITORS | LEE, CHIHYI NMN | — |
| 18462129 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | WILSON, JERICA KATLYNN | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18721811 | NOVEL ISOINDOLINONE DERIVATIVE COMPOUNDS AS CASPASE INHIBITORS | LEE, CHIHYI NMN | 1628 | §103§112 | Non-Final OA | — | Pending | Jun 19, 2024 |
| 18462129 | CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS | WILSON, JERICA KATLYNN | 1621 | §112 | Non-Final OA | — | Pending | Sep 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInnovo Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Chihyi Nmn Lee has the most, with 1 of Innovo Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
